BioPharma Credit (LSE:BPCR) Additional Paid-In Capital : $607.1 Mil(As of Dec. 2024)

View and export this data going back to 2017. Start your Free Trial

What is BioPharma Credit Additional Paid-In Capital?

BioPharma Credit's quarterly additional paid-in capital stayed the same from Dec. 2023 ($607.1 Mil) to Jun. 2024 ($607.1 Mil) and stayed the same from Jun. 2024 ($607.1 Mil) to Dec. 2024 ($607.1 Mil).

BioPharma Credit's annual additional paid-in capital stayed the same from Dec. 2022 ($607.1 Mil) to Dec. 2023 ($607.1 Mil) and stayed the same from Dec. 2023 ($607.1 Mil) to Dec. 2024 ($607.1 Mil).

BioPharma Credit Additional Paid-In Capital Historical Data

The historical data trend for BioPharma Credit's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioPharma Credit Additional Paid-In Capital Chart

BioPharma Credit Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Additional Paid-In Capital

Get a 7-Day Free Trial

607.13

BioPharma Credit Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Additional Paid-In Capital	Get a 7-Day Free Trial											607.13	-	607.13	607.13	607.13

BioPharma Credit Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

BioPharma Credit Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of BioPharma Credit's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

BioPharma Credit Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Asset Management » BioPharma Credit PLC (LSE:BPCR) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Wellington Street, Central Square, Leeds, GBR, LS1 4DL

Website

https://www.bpcruk.com

BioPharma Credit PLC is an investment company. The investment objective of the company is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The only reporting segment of the company is the investment in debt assets secured by royalties or other cash flows derived from the sale of approved life sciences products. The company generates revenue in the form of interest income, income from subsidiaries, royalty revenue, make-whole and prepayment income, dividends, and paydown fees. The company earns a majority of its revenue from Investment income.

BioPharma Credit Headlines

No Headlines